Biogen ALS Drug Showed No Benefit, O'Neill Says

Biogen ALS Drug Showed No Benefit, O'Neill Says Play

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)

  • On Air Now

    Charlie Rose Watch Now

  • Next

    Bloomberg West

blog comments powered by Disqus